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Abstract: The discovery of JAK2 V617F mutation in the mid-2000s started to fill the gap 
between clinical presentation of polycythemia vera (PV), first described by Vaquez at the 
end of the 19th century, and spontaneous erythroid colony formation, reported by Prchal and 
Axelrad in the mid-1970s. The knowledge on this mutation brought an important insight to 
our understanding of PV pathogenesis and led to a revision of the World Health Organization 
diagnostic criteria in 2008. JAK–STAT is a major signaling pathway implicated in survival and 
proliferation of hematopoietic precursors. High prevalence of JAK2 V617F mutation among 
myeloproliferative neoplasms (>95% in PV and ~50% in primary myelofibrosis and essential 
thrombocythemia) together with its role in constitutively activating JAK–STAT made JAK2 a 
privileged therapeutic target. Ruxolitinib, a JAK 1 and 2 inhibitor, has already proven to be 
efficient in relieving symptoms in primary myelofibrosis and PV. In the latter, it also appears to 
improve microvascular involvement. However, evidence regarding its potential role in altering the 
natural course of PV and its use as an adjunct to current standard therapies is sparse. Therapeutic 
advances are needed in PV as phlebotomy, low-dose aspirin, cytoreductive agents, and interferon 
alpha are the only therapeutic tools available at the moment to influence outcome. Even though 
several questions are still unanswered, this review aims to serve as an overview article of the 
potential role of ruxolitinib in PV according to current literature and expert opinion. It should 
help hematologists to visualize the place of this tyrosine kinase inhibitor in the field of current 
practice and offer criteria for a careful patient selection.
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Introduction
Polycythemia vera (PV) is a myeloproliferative neoplasia (MPN) characterized by an 
absolute increase in red blood cell mass, reflecting a clonal stem cell disorder, variably 
associated with leukocytosis and/or thrombocytosis along with hepatosplenomegaly. 
Its first description by Louis Henri Vaquez,1 a French internist, dates back to more than 
a century ago (1892). His report narrating the case of a 40-year-old patient suffering 
from a special cyanosis accompanied by excessive and persistent erythrocytosis together 
with the series of cases published by William Osler a few years later served as the first 
clinically accurate descriptions of this pathology.2 Potentially severe vascular complica-
tions, both thrombotic and hemorrhagic, determine prognosis in the early years after 
diagnosis. Even more alarming are late events, such as leukemic and myelofibrotic 
transformations, which carry a bleak outcome. For instance, leukemic transformation 
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has a median survival of ~2–5 months only, except for some 
rare cases cured after stem cell transplantation.3
Available treatments consist of phlebotomy, cytoreductive 
agents (hydroxyurea [HU] as first line, followed by busulfan 
or pipobroman), and interferon a (IFN-a). Age >60 years and 
a past medical history of thrombosis are the main risk strati-
fiers for treatment decision.4 They help guide the decision to 
initiate cytoreductive therapy in high-risk groups, depending 
on the estimated risk of vascular thrombotic events.5
The biological mechanism of the “myeloproliferative 
activity of the bone marrow” recognized by Dameshek6 
in the early 1950s was identified almost 25 years later by 
Prchal and Axelrad7 as in vitro spontaneous erythroid colony 
formation in samples of patients suffering from PV. This 
observation along with a hypersensitivity to erythropoietin 
(EPO) of erythroid PV precursor cells8,9 focused research 
efforts on implicated signaling pathways, thus leading to the 
simultaneous discovery of a mutation at amino acid position 
617 in the JAK2 by four groups.10–13 This mutation, which 
leads to a steadily increased JAK2 activity, explains cytokine 
hypersensitivity and is able to reproduce polyglobulia in 
mouse models.10–13 This phenomenon marked JAK2 V617F 
mutation as a main oncogenic event in PV pathogenesis 
and opened the gate to the idea of targeted tyrosine kinase 
inhibitors.
The first study on ruxolitinib (then called INCB018424) 
was released in 2010 by Quintás-Cardama et al,14 demonstrat-
ing a potential impact of JAK1 and JAK2 (JAK1/2) inhibition 
on the treatment of myeloproliferative neoplasms. Ruxolitinib 
was initially approved for the treatment of primary myelo-
fibrosis (MF). It is now also the first oral JAK1/2 inhibitor 
approved in the setting of HU-intolerant or -resistant PV 
patients. Recent Phase II and III studies could demonstrate 
its efficacy on controlling symptoms and disease parameters, 
such as hematocrit or spleen size in PV.15,16 The potential 
ability of ruxolitinib to influence PV outcome and its trans-
formation into secondary MF and/or acute myeloid leukemia 
remains to be proven. Since blasts in leukemic transformation 
are JAK2 V617F negative in a significant proportion of PV 
patients, a major impact of ruxolitinib on this phenomenon 
appears to be unlikely.17
PV clinical characteristics and 
paradigm of current treatment
PV is rare in patients under the age of 40 years (<5% of 
cases), with a median age at diagnosis of 60 years. It entails 
a small male predominance, with an incidence of about 
1/100,000 individuals in Western countries.18,19 Only rare 
families with an inherited increased risk of developing PV 
have been described.20 An autosomal dominant transmission 
mechanism has been outlined by the recent discovery of germ 
line predisposition genes to familial myeloid neoplasms.21 
A large retrospective study conducted on a cohort of 1,545 
patients by an international working group showed that the 
natural course of PV is marked by a 15-year cumulative risk 
to develop secondary MF or acute leukemia of about 35% 
and 5%, respectively.22
Patients should be treated according to international 
guidelines or in clinical studies. Currently, the  most fre-
quently used international guidelines for PV treatment are 
those of the European Leukemia Net23 and the British Com-
mittee for Standards in Haematology.24 Clinical follow-up 
should be performed on a regular basis for disease symp-
toms assessment, using tools such as the MPN-10 score.25 
Hematocrit control targeting less than 45%, as proven in the 
CYTO-PV trial, should be considered the aim of treatment, 
as it significantly decreased the rate of major thrombotic 
events compared to patients with a hematocrit between 
45% and 50%.26,27 Some experts suggest a target <42% 
in females, but these data are currently not yet published. 
Phlebotomy remains the standard therapy in low-risk and 
some intermediate- risk patients, as long as it achieves hema-
tocrit control without inducing severe thrombocytosis and/
or excessive iron depletion. High-risk patients are generally 
treated with HU as first-line therapy. Pegylated IFN-a 2a 
is a good alternative with a reported 76% hematological 
response rate.28
Hematocrit control is a priority over the normalization 
of a possible concomitant thrombocytosis.29 Somewhat sur-
prising and contrary to essential thrombocythemia (ET),30 
decreased incidence of thrombotic events has not been linked 
to a definitive platelet count threshold neither at baseline nor 
during the course of the disease in PV.31 In PV, clear evidence 
for controlling thrombocytosis or leukocytosis in addition to 
the defined cutoff hematocrit level is lacking at the moment.
Patient treatment is currently based on the prevention 
of vascular complications, with late events such as second-
ary MF and leukemic transformation not being addressed. 
In this line of thinking, it is remarkable to see that no suf-
ficiently powered trial is trying to evaluate the influence of 
ruxolitinib on thrombotic complications, as cardiovascular 
events account for almost half of the fatal outcomes reported 
in the ECLAP study.32,33 This seminal study demonstrated 
the value of aspirin for primary cardiovascular prevention in 
PV.33 Therefore, patients without any contraindications should 
receive low-dose aspirin therapy, given its favorable impact 
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on cardiovascular outcome, by reducing nonfatal ischemic 
strokes and venous thrombotic events, without a significant 
rise in hemorrhagic events. IFN-a is mostly considered as a 
second-line therapy. A main concern regards its side effects. 
In some cases, it can be considered a front-line alternative, 
as, for example, in pregnant or young patients.24
Pathogenesis of PV and potential 
therapeutic targets
At present, our understanding of PV remains incomplete, 
with a lot of gaps still to be filled in order to obtain a whole 
picture. However, some important advances have been made. 
First, the spontaneous proliferation of erythroid precursors 
in the in vitro setting was observed in the mid-1970s.7 This 
phenomenon represented one of the minor diagnostic criteria 
in the 2008 World Health Organization definition of PV but 
does not figure any longer in the 2016 revised revision.5,34 
During the 1980s, works of several groups pointed out the 
EPO hypersensitivity of PV erythropoietic progenitor cells 
from peripheral blood and in some cases even their EPO 
independency to form colonies.8,9 In the 1990s, this phe-
nomenon was complemented by the discovery of increased 
reactivity to other cytokines, such as interleukin 1, interleukin 
3, granulocyte macrophage colony-stimulating factor, and 
insulin-like growth factor 1.35,36
Biochemical background of V617F point mutation in 
JAK2 is a substitution of phenylalanine for valine at amino 
acid position 617 (V617F) of the JH2 domain. This gain of 
function mutation results in a permanent activation of JAK2.37 
Because of the close interaction of the JAK–STAT pathway 
with the EPO receptor, this mutation offered the first explana-
tion to the above-mentioned clinical observations. STAT, once 
phosphorylated by JAK2, works as an important transcription 
factor involved in survival, proliferation, and differentiation 
of hematopoietic precursors. In experimental models with 
knock-in mice expressing JAK2 V617F mutation, disease 
phenotype could be reproduced, verifying the hypothesis of 
its central part in pathogenesis.38
The high prevalence of JAK2 V617F mutation in PV 
(>95%) and other MPN, such as ET and primary MF (~50%), 
leads to a high level of suspicion that this event is a major 
early oncogenic event. Initiation of a clonal disease from a 
single cell harboring V617F as a sole mutation39 and devel-
opment of a condition mimicking PV with secondary MF in 
mouse models as published in 2006 by Lacout et al38 sug-
gest its driver role in initiation and evolution of the disease. 
However, Theocharides et al17 made the discovery that at the 
time of leukemic transformation, nine of their 17 patients 
presented JAK2 V617F-negative blasts. Microsatellite 
analysis along with clonality testing suggested a common 
JAK2 V617F-negative ancestor as a possible mechanism. 
 Nussenzveig et al40 went further showing that somatic JAK2 
V617F mutation was not the PV-initiating event by demon-
strating the presence of homozygous wild-type pathological 
erythroid-forming colonies in patients harboring a mutated 
status. This work revealed allelic frequencies of <50% 
(using a real-time polymerase chain reaction assay) in three 
of ten patients. Reasonable suspicion about the fact that 
JAK2 V617F mutation is not the primary event is nowadays 
accepted, speaking against a single-hit theory.
JAK2 V617F homozygosity is found in 30% of PV 
patients and is a lot less frequent in ET. Scott et al41 sug-
gested a double-hit theory leading to the transformation of 
heterozygous ET patients to PV phenotype. This phenom-
enon, although rare, highlights the possibility of a disease 
continuum between V617F-positive ET and PV.
Current murine models are still focused on the JAK2 
V617F mutation to explain the phenotype and the natural 
history of the disease, without taking into account earlier 
events. Nonetheless, these models serve as a powerful tool 
to study the consequences of mutant JAK2 allelic changes 
and their role in MPN phenotypes.
Other interesting therapeutic targets have been identified 
by basic research. For instance, Yan et al42 and Walz et al43 
demonstrated that the suppression of STAT5 expression was 
able to reverse the PV phenotype in murine models. When 
focusing on JAK2, we must recall that other mutations 
besides V617F, for example, in exon 12 have been discovered 
and account for ~4%–5% of cases.44 Exon 12 mutations of 
JAK2 correlate with a mainly erythrocytemic phenotype and 
are usually not associated with significant thrombocytosis or 
leukocytosis.44
Finally, the JAK2 V617F mutation can also be found in 
lymphoid lineages and even in endothelial precursor cells 
in patients with PV.45 Therefore, this mutation may play 
a direct role in thrombosis risk apart from provoking an 
elevated hematocrit level later on, as its presence has also 
been discovered in liver endothelial cells in some patients 
with Budd–Chiari syndrome and PV.46
Pharmacodynamics of ruxolitinib
Ruxolitinib acts by competing with adenosine triphosphate 
binding in the JAK2 catalytic site. Preclinical data demon-
strate selective growth impairment of PV erythroid progenitor 
colonies through a dose-dependent mechanism of induced 
apoptosis and reduced cell proliferation. Inhibition of JAK 
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provokes a downstream hypophosphorylation of STAT.47 
In primary cultures, ruxolitinib preferentially suppresses 
erythroid progenitor colony formation from JAK2 V617F-
positive patients (50% inhibitory concentration, IC
50
 =67 nM) 
as compared to healthy donors (IC
50
 =407 nM).14 However, 
this mutation is neither a specific nor an exclusive target 
of ruxolitinib as the drug also inhibits JAK1 and wild-type 
JAK2.14 This ubiquitary inhibition explains the hematologi-
cal side effects, such as anemia and thrombocytopenia, by 
inhibiting both EPO and thrombopoietin signaling even in 
normal lineages.48 Further studies could help to individualize 
therapeutic concentrations of ruxolitinib.
Decreasing the levels of inflammatory cytokines, as 
demonstrated in murine models, may be another mechanism 
of action by ruxolitinib on symptom relief. Its significance 
in PV is certainly a lot lower than in MF, where the role of 
proinflammatory cytokines is more apparent. However, these 
cytokines are also detectable in PV patients and may serve 
as a stimulus to clonal erythroid growth. As JAK1 also plays 
a key role in the signaling of certain cytokines, its inhibition 
may also contribute to some therapeutic effect.
Long-term data in advanced cases of MPNs such as post-
PV MF undergoing allogeneic transplantation are needed.49 
Ruxolitinib may reduce treatment-related complications by 
improving symptoms in the pretransplant setting, but data on 
its influence on transplant outcome are sparse. Data suggest-
ing some influence on bone marrow fibrosis in MF should 
encourage incorporating its evaluation in future trials.
Another important point is the mechanism of ruxolitinib 
resistance in PV clones. In contrast to BCR-ABL-positive 
MPNs, compensating point mutations in kinase domains have 
not been identified in humans suffering from JAK-2-positive 
neoplasms yet. This observation leads to alternative hypoth-
eses. In particular, selective pressure of JAK1/2 inhibition 
may be easily overwhelmed by alternative pathway activation. 
An insufficient inhibition of STAT5 pathway is not likely, as 
the high potency of ruxolitinib to hypophosphorylate STAT5 
has been demonstrated. Even with this potent blockage, 
complete hematological responses in the RESPONSE trial 
are observed in only 24% of patients, as opposed to a much 
higher rate in most tyrosine kinase inhibitor treatments for 
BCR-ABL-positive malignancies, highlighting the theory of 
alternative pathways.16
Pharmacokinetics of ruxolitinib
A pharmacokinetic study conducted on healthy subjects 
with radiolabeled ruxolitinib attested rapid absorption, and 
high solubility with peak plasma concentration reached in 
<2 hours. Food intake does not seem to impact significantly 
on drug bioavailability, which is >95%. In plasma, the drug 
is 97% protein bound, mostly with albumin. Plasma half-life 
is ~3 hours.50
Ruxolitinib is extensively metabolized by cytochrome 
3A4 into less active metabolites and is subject to significant 
pharmacodynamic interactions that prescribers should be 
aware of. Modified dosing should be considered when ruxoli-
tinib is prescribed in combination with CYP3A4 inhibitors, 
such as conazole-antimycotics (ketoconazole, fluconazole), 
or certain antibiotics, such as erythromycin. An estimated 
reduction of 50% should be considered with strong enzymatic 
inhibitors in light of data available in healthy volunteers.51 
Pharmacodynamic properties seem to be less affected in 
the setting of concomitant inducers administration, such as 
rifampicin, and a dose adaptation is generally not indicated.
Active metabolites maintain a significant pharmacody-
namic activity accounting for ~20% in laboratory assays. 
Daily intake does not lead to significant parent compound 
and drug metabolites accumulation. Urinary excretion of 
metabolites accounts for almost three-quarters of elimination 
route and the remaining quarter is found in feces, with <1% as 
an intact compound. Ruxolitinib exhibits both a monophasic 
and a biphasic decrease with a mean half-life of 2.3 hours 
and 5.8 hours, respectively.52 In the setting of mildly impaired 
renal function, concern regarding accumulation of active 
metabolites should lead to dose reduction, based on initial 
platelet count and close follow-up.51 Therapy should be sig-
nificantly reduced or even completely avoided in patients with 
severe renal failure (creatinine clearance <15 mL/min) and 
in patients with baseline platelet count <100 G/L, according 
to available data and common expert opinion.51 Regarding 
hepatic dysfunction, Chen et al53 did not find a relationship 
between its severity and systemic exposure to ruxolitinib 
(area under the curve). In this case, starting dose based on 
platelet count should be reduced by ~50%.
RESPONSE to ruxolitinib
Ruxolitinib has proven its efficacy in the recently published 
Phase III RESPONSE trial.16 This study compared ruxolitinib 
to standard therapy in a cohort of 222 PV patients with unac-
ceptable side effects of or inadequate response to HU. The 
latter was defined as a required dose ≥2 g/d or an inferior 
maximum tolerated dose resulting in hematotoxicity or failure 
to control leukocytosis, thrombocytosis, hematocrit level, or 
splenomegaly. Randomized in a 1:1 fashion, this patient cohort 
had a mean age of ~60 years, good performance status for the 
vast majority, and a long course of disease of 8–9 years since 
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diagnosis. The studied treatment dose of ruxolitinib was 10 mg 
twice daily. The primary end point was hematocrit control and 
reduction of spleen size of at least 35% at 8 months after ran-
domization. In the ruxolitinib arm, 60% and 38% of patients 
showed either hematocrit control or spleen volume reduction, 
respectively. Interestingly, only 21% of patients achieved the 
composite end point, indicating that one parameter is not 
closely related to the other. Spleen volume reduction was 
chosen as one primary end point because splenomegaly is 
associated with a decreased survival and with a higher symp-
tom burden. Important symptom relief was reached in 49% of 
patients treated with ruxolitinib versus 5% in the control arm. 
Phlebotomy dependency was also decreased with supposed 
consecutive reduction in related side-effects (Tables 1–3). 
Both of these results represent a real value in clinical practice. 
While phlebotomy is very effective, its long-term feasibility 
is limited, due to the development of severe iron deficiency 
and its side effects both hematologically (eg, thrombocytosis) 
and systemically (eg, skin problems).
A point of criticism is the choice of the hematocrit level 
as the only surrogate for thromboembolic risk. A second 
criticism is the choice of a 35% spleen size reduction cut-
off, as patients with important splenomegaly would still be 
symptomatic even after this relative downsizing. The 35% 
spleen size reduction was chosen, as it was already an end 
point in the COMFORT-II study.54 The rationale was based 
on the observation that a 50% reduction in spleen length was 
roughly equivalent to a 35% reduction in spleen volume.55 
Another point is that 58% of patients in the standard arm were 
still on HU treatment at randomization. Despite the above-
mentioned limitations, the study demonstrated the efficacy 
of ruxolitinib (24% of complete hematological responses vs 
1%) as attested by an impressive crossover of 86% of patients 
to ruxolitinib. Consequently, it is unlikely to obtain data on 
a potential effect on transformation rates into MF or acute 
myeloid leukemia during the ongoing cohort monitoring.
Side effects of ruxolitinib
Ruxolitinib is well tolerated in PV with 85% of patients 
still on treatment at 2 years of follow-up.16 Most frequent 
adverse events consist of myelosuppression, gastrointestinal 
toxicity, and an immunosuppression including an elevated 
risk of infection and reactivation of herpes viruses and other 
infectious agents controlled through cellular immunity. The 
Table 1 Adverse clinical events during ruxolitinib treatment
RESPONSE16 COMFORT-I77 COMFORT-II54
n=110 n=155 n=146
Bruising 18.7%
Peripheral 
edema
22%
Asthenia 18%
Nasopharyngitis 16%
Pyrexia 14%/2%
Nausea 13%
Arthralgia 12%
Diarrhea 14.5% 23%
Dizziness 14.8%
Headache 14.8% 10%
Dyspnea 10%/2.7% 16%
Muscle spasms 11.8%
Abdominal pain 9.1% 11%/3%
Weight gain 7%
Flatulence 5% 10%/2%
Notes: RESPONSE: adverse events (all grades) with a frequency more than two 
times higher than in the best available therapy group. COMFORT-I/II: adverse events 
(all grades) with a frequency at least 5% higher than in the placebo group. Bold = 
Grades 3–4 (according to NCI CTCAE 3.0).
Table 2 Adverse laboratory events during ruxolitinib treatment
Laboratory parameters RESPONSE16 COMFORT-I77 COMFORT-II54
Anemia 43.6% 96.1%/45.2% 42%
Thrombocytopenia 24.5% 69.7%/30.5% 68%
Neutropenia 18.7%
gGT 46.4%/7.3%
Hypercholesterolemia 42.7%
Hypertriglyceridemia 20.9%
High lipase 31.8%
ALAT 31.8%
ASAT 28.2%
Creatinine (high) 28.2%
Hypercalcemia 17.3%
Notes: RESPONSE: laboratory parameters adverse events (all grades) with a frequency at least 5% (hematological) and 10% (nonhematological) higher than in the best 
available therapy. COMFORT-I/II: hematological adverse events (all grades) with a frequency at least 10% higher than in the placebo and best available therapy groups, 
respectively. Half of grades 3–4 anemias and thrombocytopenias occurred in the first 8 weeks of treatment initiation. Thrombocytopenia was the most important cause of 
dose interruption/modification in Phase III trials (40%–50%). Dose reduction is advocated for any hemoglobin <100 g/L and/or platelet count <75 G/L (it should be considered 
already if <100 G/L). Case series of “ruxolitinib withdrawal syndrome” defined as an acute worsening of disease-related symptoms, parameters, and splenomegaly of varying 
severity have been described in MF patients. Bold = Grades 3–4 (according to NCI CTCAE 3.0).
Abbreviations: gGT, gamma-glutamyl transferase; ALAT, alanine aminotransferase; ASAT, aspartate aminotransferase; MF, myelofibrosis.
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Table 3 Summary of evidence in treating PV patients with ruxolitinib
Name Verstovsek et al15 RESPONSE16 RELIEF56
Type of study 
(number of patients)
Phase II (34) Phase III (222) Phase III (110)
Purpose Investigate clinical activity Evaluate efficacy of ruxolitinib versus 
standard therapy in patients who had 
an inadequate response to or had 
unacceptable side effects from HU
Design Single arm Randomized 1:1 (n=110:112) Randomized 1:1 (n=54:56)
Patients 
characteristics
Median age (years): 57.5
Median months since 
diagnosis: 115
Advanced disease status: HU 
refractory or intolerant
Median Ht: 46.7%
Two or more phlebotomies in 
the previous 6 months: 70.5%
Phlebotomy-dependent patients with 
splenomegaly
Median age (years): 62/60
Median months since diagnosis: 8.2/9.3
Median phlebotomies in the previous 
6 months: two in both arms
Median duration of previous HU 
treatment (years): 3.1 versus 2.8
Stable dose of HU with PV-related symptoms score 
≥8 on the Myeloproliferative Neoplasm Symptom 
Assessment Form (MPN-SAF)
Trial comparator Standard therapy
Median follow-up 
(months)
35.4
Primary outcome/
results
Responsea
Ht <45% without 
phlebotomies: 97%
Nonpalpable spleen: 44% 
and 63% at 24 months and 
144 months, respectively
Improvement in night sweats, 
pruritus, bone pain (observed 
<4 weeks after initiation of 
therapy)
Composite: Ht control and spleen size 
volume reduction of 35% or more from 
baselineb
Ht control: 60.0% versus 19.6%
Spleen volume reduction: 38.2% versus 
0.9%d
The primary end point was the proportion of 
patients with a ≥50% reduction in TSS-C at week 16
87.0% and 89.3% remained on treatment through 
week 16. 43.4% in the RUX group and 29.6% in the 
HU group (P=0.139; OR, 1.82; 95% CI, 0.82–4.04). 
The proportions of patients in the RUX vs HU 
groups achieving a ≥50% reduction in scores for 
itching and tiredness at week 16 were 40.0% versus 
26.4% and 54.2% versus 32.0%, respectively. 34% 
response rate among patients who continued to 
receive a stable HU dose suggests a placebo effect 
that led to an underpowered study
Secondary 
outcome
Symptomatic benefitc:
49% versus 5% in the control arm
The mean change in the JAK2 V617F allele 
burden from baseline was −12.2% versus 
1.2% in the standard-therapy groupb
The allele burden decreased steadily over 
time in the ruxolitinib group
Secondary end points included proportion of 
patients with a ≥50% reduction in individual TSS-C 
symptoms and safety
Comments 85.7% assigned to standard therapy 
crossed over to ruxolitinib at or after 
assessment time
Notes: aAssessed by European Leukemia Net criteria. bAssessed at 8 months; spleen size measurement by means of centrally reviewed MRI or CT studies. cAssessed by 
Myeloproliferative Neoplasm Symptom Assessment Form (MPN-SAF total symptom score). dAt least one component of the primary end point occurred in 77.3% of patients 
in the ruxolitinib group.
Abbreviations: HU, hydroxyurea; PV, polycythemia vera; TSS-C, cytokine total symptom score; RUX, ruxolitinib; OR, odds ratio; MRI, magnetic resonance imaging; CT, 
computed tomography; Ht, hematocrit; CI, contraindication.
most common side effect is bone marrow depression ranging 
from unilineage cytopenia to pancytopenia. Before starting 
therapy, a full blood count is needed and dose of ruxolitinib 
should be adapted depending on the platelet count. Under 
therapy, regular controls of full blood count are needed, 
as cytopenia is likely to develop. Dose adaptation or even 
therapy interruption may be required. Additional common 
side effects are vertigo, constipation, herpes zoster, and 
urinary tract infections. A high proportion of patients gained 
weight (Tables 1 and 2).
Practicians must be aware that cases of nonmelanoma 
skin carcinomas have been reported in patients treated with 
ruxolitinib. A causal relationship is not clearly established, due 
to previous use of other therapies, age of the concerned popu-
lation, and the presence of premalignant lesions in some cases.
Sporadic life-threatening cases of progressive multifo-
cal leukoencephalopathy due to JC virus reactivation have 
been associated to JAK signal inhibition, but as these are 
rare events, the prevalence of this serious condition cannot 
be quantitated.
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Place of ruxolitinib in current 
clinical practice: for which patient 
and when?
The RESPONSE trial demonstrated similar efficacy in 
spleen size reduction after 1 year in PV patients as did the 
COMFORT-II study in MF patients.16,54 These two well-
powered Phase III studies showed sufficient evidence for 
a significant benefit in patients suffering from disabling 
abdominal discomfort due to splenomegaly. Improvements 
of itching, constitutional symptoms (ie, night sweats), bone 
pain, and iron stores have also been demonstrated (Table 2). 
The above-mentioned clinical benefits should be the stron-
gest reasons to initiate ruxolitinib treatment in the light of 
available data, provided that these symptoms persist under 
the standard treatment available.
Is there an indication to switch therapy in the case of a 
PV well controlled by HU but with persistence of disabling 
symptoms? The RELIEF study tried to answer the ques-
tion by including PV patients on a stable dose of HU for at 
least 3 months with PV-related symptoms.56 This placebo- 
controlled randomized Phase IIIb study revealed a positive 
trend for a switch to ruxolitinib regarding symptom relief, but 
this trend did not prove statistically significant, and the abstract 
presentation at the 2014 American Society of Hematology 
has not yet been followed by a full publication.56 Symptoms 
were assessed according to the Myeloproliferative Neoplasm 
Symptom Assessment Form and the cytokine total symptom 
score and included evaluation of tiredness, itching, muscle 
aches, and night and daytime sweats. An unexpected placebo 
effect of 34% in symptoms improvement in the HU arm 
resulted in the underpowering of the study; a clear statistically 
significant difference could not be demonstrated. Nonethe-
less, after 4 months of treatment, individual symptoms such 
as itching and night sweats reached a median improvement 
from baseline of 40% and 68%, respectively.
The data on long-term outcome of PV patients treated 
with ruxolitinib are sparse. Most mature data come from 
MF cohorts in Phase III studies. A pooled analysis of overall 
survival (OS) from COMFORT-I and -II trials suggested an 
improved survival in ruxolitinib-treated arms (after 3 years of 
follow-up) with a crossover-corrected ratio of 0.29. Patients 
with intermediate- and high-risk features showed a survival 
benefit, although survival was only a secondary end point 
in both trials. These study results in MF patients should 
encourage future studies to address the question of survival 
improvement as a primary end point in PV patients treated 
with ruxolitinib, although pathogenesis, disease characteris-
tics, and survival are different in this pathology.57,58
The ongoing Phase III trial RESPONSE-2 addresses 
hematocrit control in HU-intolerant or -resistant PV patients 
without palpable splenomegaly. The sponsoring pharmaceuti-
cal company has announced that this primary end point has 
been met. Some of its secondary end points include assess-
ment of thrombosis and hemorrhagic and transformation 
events. First results addressing these questions are awaited 
for 2020. The British MAJIC randomized Phase II trial will 
also provide data on OS and thromboembolic event rate as 
secondary outcomes. Interestingly, histological (bone marrow 
biopsies) and molecular (JAK2 V617F burden) responses 
will also be examined.
Future study design in PV
A median survival of 15 years with a median age at diagno-
sis of 60 years makes treatment influence on survival of PV 
difficult to assess. Bone marrow changes, both event- and 
complication-free survival, and quality of life improvement 
may be end points of interest for future studies.59 Addition-
ally, risk factors possibly associated with a shortened survival 
in PV (such as hematocrit levels, leukocytosis, and JAK2 
V617F allele burden) might be used as best surrogate mark-
ers for improvement of OS.60 In particular, JAK2 V617F 
allele burden could be used to monitor treatment efficacy, 
as allele burden can reflect PV progression. However, allele 
burden reduction by treatment has not yet been demonstrated 
as a surrogate of better outcome. In a Phase II study by Ver-
stovsek et al,15 JAK2 V617F allele burden reduction attained 
20% in 42% of ruxolitinib-treated patients. In mice, gene 
expression level is correlated with disease phenotype, and 
allele burden control may have a different impact between 
individuals.61 High allele burden also seems to be a predictive 
risk factor for MF progression of PV, as it has been recently 
demonstrated, not only in mouse models but also in patients 
suffering from PV.60
Unfortunately, large studies are clearly designed to 
achieve fast drug approval rather than trying to offer best 
achievable evidence of both clinical and survival benefit. 
This approach impairs investigation of drug combinations 
and knowledge of disease behavior.
Future concepts and potential 
combination therapies
Intensifying response through combination therapies will cer-
tainly be one of the next steps in PV approach. Our  knowledge 
of other active compounds in PV may be the best way to 
identify potentially synergistic drug associations. Beneficial 
IFN-a action, although unclear in many points, seems to 
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ensue from a combination of direct effects on PV and normal 
stem cells in conjunction with immune-mediated response 
modulation. However, how exactly these mechanisms work 
together and how they can provoke a response rate of roughly 
60% in patients suffering from PV are unknown.62 IFN-a 
signaling plays a role in effector CD4 lymphocyte survival 
and leads to decreased allele burden in some cases and also 
to polyclonal hematopoietic resurgence.63,64 Total dissociation 
in the two aforementioned events has been reported and is 
consistent with the existence of a proliferative/differentiating 
effect on normal quiescent stem cells on the one hand and 
a cytostatic action on PV progenitors on the other.65 Down-
stream signaling of IFN-a transduction through JAK1 and 
TYK2 allows putting forward the hypothesis that the combi-
nation of IFN-a with a selective JAK2 inhibitor could act in 
a complementary way. Feasibility, safety, and an impressive 
response in a patient treated with IFN-a concomitantly to 
ruxolitinib have been published in 2014.66
Possibly, elucidation of pathophysiological mechanisms 
will lead to the development of targeted therapy. PI3K/mTOR 
pathway demonstrated its implication in survival of JAK2-
positive human cell lines as its inhibition showed an enhance-
ment of ruxolitinib apoptotic activity, opening the way for 
future Phase II studies.67 Another interesting approach would 
be to target downstream important effectors of JAK such as 
STAT5. Furthermore, accumulation of reactive oxygen spe-
cies as a consequence of JAK–STAT hyperactivity leads to 
DNA damage and genetic instability.10,68 Anti-inflammatory 
properties of ruxolitinib could also be exploited in the 
future.69 Other pathological circumstances are being discov-
ered, as, for example, change of microenvironment in JAK2 
V617F-positive MPNs with reduction of sympathetic nerve 
fibers and Nestin+ mesenchymal cells in the bone marrow 
of these patients. These discoveries are leading to upcom-
ing drugs other than JAK inhibitors with influence on allele 
burden, as, for example, beta-mimetics, studied currently in 
Phase II in Switzerland (NCT02311569). MPN cells are held 
responsible for destroying cells of the microenvironment, an 
effect that could be proven reversible in a mouse model under 
beta-mimetic treatment.70
Other potential JAK inhibitors
Highly selective JAK2 V617F inhibition is a logic alternative 
to JAK1/2 inhibition and is now currently under investigation. 
Fedratinib, a selective JAK2 inhibitor, showed encouraging 
symptomatic benefit in patients suffering from MF, includ-
ing post-PV and post-ET patients, according to the interim 
analysis of the JAKARTA-2 study released as an abstract in 
2013.71 A previously published Phase I study conducted by 
Pardanani et al72 showed high normalization rates of platelet 
and leukocyte counts in MF. However, the development of 
fedratinib was stopped in 2013 while in Phase III, when the 
US Food and Drug Administration ordered immediate inter-
ruption of all ongoing studies with this molecule for safety 
reasons as a consequence of reports that study subjects were 
developing Wernicke’s encephalopathy.73
Other JAK2 inhibitors are on their way, such as mom-
elotinib, which appears to exert a beneficial effect on sple-
nomegaly and on anemia in patients with MF,72 pacritinib, 
which is currently in Phase II and III studies,74 and CHZ868.75
Summary
While ruxolitinib seems to be a potent drug to treat symptoms 
of splenomegaly and cytokine effects, these problems are less 
prominent in PV than in MF patients. Phlebotomy, low-dose 
aspirin, and cytoreduction with HU or IFN-a will remain 
the backbone of treatment for the time being, as indicated 
by current guidelines from the European Leukemia Net23 
and the British Committee for Standards in Haematology.24
As JAK2 mutations do not seem to be the first mutational 
event in the development of PV and since blast cells in leu-
kemic transformation often do not show the JAK2 V617F 
mutation, the most feared PV complication, transformation 
to acute myeloid leukemia, will probably not be influenced 
by ruxolitinib treatment. Finally, in patients undergoing stem 
cell transplantation, it cannot be recommended to pretreat 
them with ruxolitinib outside clinical studies.
There are certainly PV patients benefiting from ruxoli-
tinib; however, these patients must be carefully selected. 
Ruxolitinib’s place in current practice should be directed 
toward disease-related symptoms relief after failure of stan-
dard treatment. Of particular note, the beneficial effect of 
ruxolitinib is not limited to patients with a positive mutational 
status, indicating that the drug is not specific for the PV clone. 
In fact, ruxolitinib is a good drug to address symptomatic 
burden, but less so the allelic one. Disease-related problems, 
such as itching, can effectively be treated with ruxolitinib, if 
they do not disappear with standard treatments, such as HU.
In PV, in which life expectancy can approach a near-
normal range, the primary treatment goal is still prevention 
of thromboembolic events that account for most of the 
deaths in this pathology. As yet, no study on ruxolitinib has 
addressed the question of its influence on thrombotic events, 
and ruxolitinib cannot be considered as a first-line treatment 
from this point of view either. However, a meta-analysis 
from COMFORT-I, COMFORT-II, and RESPONSE trials 
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(including 750 patients) provided data showing a significant 
reduction in thrombosis rate among patients treated with 
ruxolitinib with a risk ratio of 0.45 in comparison to placebo 
and best available therapies.76 Despite similar risk ratio, 
subgroup analysis of arterial and venous thrombosis did not 
reach statistical significance in this heterogeneous patient 
group containing both MF and PV patients. It is difficult to 
conclude if this potential benefit impacts more on the arterial 
or venous system or both, without future trials addressing this 
specific question in PV patients as well as MF patients only.
Another question to address is the longevity of symptom 
relief. If the expected benefit will be limited to only 1–3 years, 
ruxolitinib may not be a good option, at least in the beginning 
of PV treatment. Further studies on long-term outcome are 
needed to address this question. Additionally, treatment inter-
ruption among study patients was quite frequent, not only 
due to loss of response but also due to toxicity, allowing the 
rebound phenomenon of cytokine effects to become a real 
problem, even in PV.
Conclusion
A concerted discussion between a patient and his/her hema-
tologist, balancing costs, side effects, and expected benefit 
from therapy, has to precede prescription. The patient has to 
be thoroughly informed about ruxolitinib side effects, partic-
ularly as the drug does not seem to have disease- modulating 
action and OS improvement is marginal, if existent at all. 
Careful management of myelosuppressive, infective, and 
gastrointestinal side effects with a thorough blood count 
survey and regular follow-up are the cornerstones of good 
practice. A final but not trivial point to consider is that treat-
ment costs are quite high.
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